Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma

Abstract Alterations in transcriptional programs promote tumor development and progression and are targetable by bromodomain and extraterminal (BET) protein inhibitors. However, in a multi‐site clinical trial testing the novel BET inhibitor, PLX51107, in solid cancer patients, liver metastases of uv...

Full description

Bibliographic Details
Main Authors: Vivian Chua, Marlana Orloff, Jessica LF Teh, Takahito Sugase, Connie Liao, Timothy J Purwin, Bao Q Lam, Mizue Terai, Grazia Ambrosini, Richard D Carvajal, Gary Schwartz, Takami Sato, Andrew E Aplin
Format: Article
Language:English
Published: Wiley 2019-02-01
Series:EMBO Molecular Medicine
Subjects:
BET inhibitor
FGF2
FGFR
liver
uveal melanoma
Online Access:https://doi.org/10.15252/emmm.201809081

Internet

https://doi.org/10.15252/emmm.201809081

Similar Items